← Leaderboards
Carol S Dukes-Hamilton
Duke University
$2,014,219
Attributed
$2,014,219
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$2,014,219 · 3
By mechanism
M01$2,014,219 · 3
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Russell E Ware$48,672,245
- John H Sampson$43,413,436
- Rebecca H Buckley$9,502,389
- Nirmish R Shah$4,694,415
- Eli Gilboa$17,521,988
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchDrug Screening /EvaluationHiv InfectionsHuman Therapy EvaluationDrug Adverse EffectPharmacokineticsCombination ChemotherapyAids TherapyTuberculosisAntiaids AgentAntitubercular AgentsCd4 MoleculeComorbidityIntravenous AdministrationQuality Of LifeRelapse /RecurrenceRifamycinsInterleukin 2DosageHydroxyureaClinical Trial Phase I2'3'Dideoxyinosine
Grant awards (17)
RIFAPENTINE FOR RELAPSE AMONG HIV SEROPOSITIVE &SELECTED SERONEGATIVE$117,022
M01 · FY2002 · RR
IV OR SQRHIL2 IN HIV INFECTED SUBJECTS ON HAART$117,022
M01 · FY2002 · RR
ANTIRETROVIRAL ACTIVITY OF HYDROXYUREA ALONE AND IN COMBINATION WITH DDI$117,022
M01 · FY2002 · RR
IV OR SQRHIL2 IN HIV INFECTED SUBJECTS ON HAART$293,069
M01 · FY2001 · RR
RIFAPENTINE FOR RELAPSE AMONG HIV SEROPOSITIVE &SELECTED SERONEGATIVE$293,069
M01 · FY2001 · RR
ANTIRETROVIRAL ACTIVITY OF HYDROXYUREA ALONE AND IN COMBINATION WITH DDI$293,069
M01 · FY2001 · RR
IV OR SQRHIL2 IN HIV INFECTED SUBJECTS ON HAART$117,022
M01 · FY2001 · RR
ANTIRETROVIRAL ACTIVITY OF HYDROXYUREA ALONE AND IN COMBINATION WITH DDI$117,022
M01 · FY2001 · RR
ANTIRETROVIRAL ACTIVITY OF HYDROXYUREA ALONE AND IN COMBINATION WITH DDI$117,022
M01 · FY2001 · RR
IV OR SQRHIL2 IN HIV INFECTED SUBJECTS ON HAART$117,022
M01 · FY2001 · RR
RIFAPENTINE FOR RELAPSE AMONG HIV SEROPOSITIVE &SELECTED SERONEGATIVE$117,022
M01 · FY2001 · RR
RIFAPENTINE FOR RELAPSE AMONG HIV SEROPOSITIVE &SELECTED SERONEGATIVE$117,022
M01 · FY2001 · RR
RIFAPENTINE FOR RELAPSE AMONG HIV SEROPOSITIVE &SELECTED SERONEGATIVE$40,907
M01 · FY2000 · RR
ANTIRETROVIRAL ACTIVITY OF HYDROXYUREA ALONE AND IN COMBINATION WITH DDI$40,907
M01 · FY2000 · RR
IV OR SQRHIL2 IN HIV INFECTED SUBJECTS ON HAART$0
M01 · FY2000 · RR
RIFAPENTINE FOR RELAPSE AMONG HIV SEROPOSITIVE &SELECTED SERONEGATIVE$0
M01 · FY2000 · RR
IV OR SQRHIL2 IN HIV INFECTED SUBJECTS ON HAART$0
M01 · FY2000 · RR